YOQNEAM, Israel, March 2 /PRNewswire-FirstCall/ -- Given Imaging announced today that leading gastroenterologists from around the world will meet to discuss the latest advances in and applications for capsule endoscopy at the fourth annual International Conference on Capsule Endoscopy (ICCE) in Miami, FL from March 7th - 8th. 118 abstracts and posters will be presented to a gathering of more than 400 participants from 33 countries.
“The data to be presented at this year’s ICCE conference will show that capsule endoscopy has a positive impact on patient management,” said Dr. Blair Lewis, Clinical Professor, Medicine / Gastroenterology at Mount Sinai School of Medicine and Co-Chairman of ICCE. “Over the past few years capsule endoscopy has changed the way we diagnose and treat diseases of the small bowel. Furthermore, recent clinical data also shows that capsule endoscopy for the esophagus is an effective tool for screening Barrett’s Esophagus and Esophagitis.”
Featured ICCE lectures include: -- Capsule endoscopy as a useful tool to define the severity and extent of small bowel Crohn’s disease and to monitor mucosal healing in the treatment of the disease -- Esophageal capsule endoscopy (ECE) compared to traditional upper endoscopy when used to screen patients with end stage liver disease for detection of esophageal varices -- The impact of capsule endoscopy on patient management -- The interaction between capsule endoscopy and implantable pacemakers/defibrillators A full agenda for the ICCE is available at http://www.icce2005.org/ .
Post-ICCE Conference Webcast Information: Given Imaging will host a conference call with leading gastroenterologists to review consensus findings from the fourth annual ICCE on Tuesday, March 8th at 11:00am ET. The conference call will be webcast through the company’s website http://www.givenimaging.com/ .
About Given Imaging
Given Imaging is redefining gastrointestinal diagnosis by developing, producing and marketing innovative, patient-friendly products for detecting gastrointestinal disorders. The company is developing a complete line of PillCam video capsules for detecting disorders of the gastrointestinal tract. The company’s technology platform is the Given(R) Diagnostic System, featuring the PillCam(TM) video capsule, a disposable, miniature video camera contained in a capsule, which is ingested by the patient. The PillCam(TM) SB capsule is the only naturally ingested method for direct visualization of the entire small intestine. It is currently marketed in the United States and in more than 60 other countries and has benefited more than 170,000 patients worldwide. The PillCam(TM) ESO video capsule, which provides visual examination of the esophagus, has been cleared for marketing by the FDA. Additional capsules for visualization of the stomach and colon are under development. Given Imaging’s headquarters, manufacturing and R&D facilities are located in Yoqneam, Israel; it has direct sales and marketing operations in the United States, Germany and France, and local offices in Japan, Spain and Australia. For more information, visit http://www.givenimaging.com/ .
This press release contains forward-looking statements about Given Imaging, including projections about our business, our future revenues and our future profitability, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example, statements in the future tense, words such as “anticipates,” “estimates,” “expects,” “intends,” “plans,” “believes,” and words and terms of similar substance used in connection with any discussion of future operating or financial performance identify such forward-looking statements. Those forward- looking statements are not guarantees of future performance and actual results could differ materially from our current expectations as a result of numerous factors, including but not limited to the following: changes in regulatory environment, our success in implementing our sales, marketing and manufacturing plan, protection and validity of patents and other intellectual property rights, the impact of currency exchange rates, the effect of competition by other companies, the outcome of future litigation, the reimbursement policies for our product from healthcare payors, quarterly variations in operating results, the possibility of armed conflict or civil or military unrest in Israel and other risks disclosed in our filings with the U.S. Securities Exchange Commission.
Given Imaging Ltd.
CONTACT: Mark Gilreath of Given Imaging Ltd., +1-770-662-0870; FernLazar, flazar@lazarpartners.com, or David Carey, dcarey@lazarpartners.com,both of Lazar Partners Ltd., +1-866-GIVEN-IR, for Given Imaging Ltd.